Fluorinated phenylamino compounds and pharmaceutical compositions
US11780800B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2023 |
| Grant date | Oct 10, 2023 |
| Priority date | — |
| Expiry date | Mar 16, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C291/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.